Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015¿2020 Mark G. Wise; James A. Karlowsky; Elkin V. Lemos-Luengas; Rafael R. Valdez; Daniel F. Sahm;

In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017¿2019 James A. Karlowsky; Krystyna M. Kazmierczak; Maria Lavínea Novis de Figueiredo Valente; Elkin Lemos Luengas; Monique Baudrit; Alvaro Quintana; Paurus Irani; Gregory G. Stone; Daniel F. Sahm;

Economic evaluation of ceftazidime-avibactam vs. polymyxin B for treatment of hospital-acquired and ventilator-associated bacterial pneumonia Jessica Matuoka; Daniela Vianna Pachito; Filipe Piastrelli; Lorena Cristina Correa Fehlberg; Haliton Alves de Oliveira Junior;